Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593071 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.
A Phase 2 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,330
- Enrollment target
NCT02593071 is a Phase 2 study that has completed, run by Novavax. The registered enrollment target is 1,330 participants.
The verdict
NCT02593071, a Phase 2 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,330 participants
- Enrollment target
Study Summary
This study will enroll subjects who received the RSV F vaccine or placebo in the earlier study (RSV-E-201, Year 1) and re-randomize them to receive either vaccine or placebo in a second season. This design will permit evaluation of the safety and immunogenicity of revaccination in a second RSV season, and the safety and immunogenicity of revaccination over two years.
Interventions
- BIOLOGICAL RSV-F Vaccine
- BIOLOGICAL Phosphate Buffer Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,330 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02593071
The ClinicalTrials.gov registry entry for NCT02593071 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RSV-F Vaccine is the first listed.
NCT02593071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02593071 about?
NCT02593071 is a clinical study titled "Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.". This study will enroll subjects who received the RSV F vaccine or placebo in the earlier study (RSV-E-201, Year 1) and re-randomize them to receive either vaccine or placebo in a second season. This design will permit evaluation of the safety and immunogenicity of revaccination in a second RSV seaso...
What is the current status of trial NCT02593071?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,330 participants. The study started on 2015-10. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02593071?
The interventions under investigation include: RSV-F Vaccine (BIOLOGICAL), Phosphate Buffer Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02593071?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.